Screener
Gyre Therapeutics, Inc. GYRE Gyre — Cost of Goods Sold
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Three Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|
| 2025(As Recast) | 2025(As Recast) | |
| Revenues | $$29,734 | $$60,305 |
| Operating expenses: | ||
| Cost of revenues | 1,151 | 2,045 |
| Selling and marketing | 15,195 | 26,035 |
| Research and development | 8,351 | 16,442 |
| Research and development - related parties | — | — |
| General and administrative | 7,277 | 15,481 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s gyre — cost of goods sold?
- Gyre Therapeutics, Inc. (GYRE) reported gyre — cost of goods sold of $0 in Q2 2026.
- What does gyre — cost of goods sold mean?
- This metric captures the direct costs attributable to the production of goods or the delivery of services within the specific business segment. It includes expenses such as raw materials, direct labor, and manufacturing overhead directly linked to revenue generation. Analyzing this helps evaluate the segment's production efficiency and gross margin potential.
Ask your AI about Gyre Therapeutics, Inc.'s gyre — cost of goods sold.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude